All In Biotech

Drug Trial Radar · NCT07267299

Switching From Restasis to TRYPTYR

Efficacy of Switching Participants Treated With Restasis to TRYPTYR

Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Apr 1, 2026

Study completion May 15, 2026

Sponsor

Lead sponsor
Southern College of OptometryAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Switching to acoltremon 0.003% will significantly improve the signs and symptoms of participants who were being treated with Restasis at 28 days post-treatment compared to baseline. Dry eye disease (DED) is a prevalent condition that commonly affects patients of working age in addition to the elderly. DED is a complex condition that results in ocular symptoms such as dryness and burning and signs such as decreased tear production (aqueous deficient DED) or increased tear evaporation (evaporative DED). Unfortunately, there is not a perfect correlation between DED signs and symptoms, which makes diagnosis and timely treatment challenging.

Conditions

  • Dry Eye
  • Eye Diseases
  • Chronic Dry Eye

Interventions

  • acoltremon 0.003%Drug

    Participants who are using restasis will be switched to acoltremon 0.003%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change between pre- and post-drop in unanesthetized Schirmer test score on Day 1Time frame: 1 day

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.